Page 265 - ASHG 2013 Program Guide

252  
POSTER SESSIONS
W=W
ednesday authors will present; T=Thursday authors will present; F=Friday authors will pr
esent
3401
F A leukemic stem cell score associated with
patient prognosis and tumor histopathology in
ovarian cancer.
B. A. Logsdon, S. L. Battle, M. H. Rendi,
R. D. Hawkins, S.-I. Lee.
3402
W Coupled use of family-based exome
sequencing and TCGA germline data analysis to
identify novel breast and ovarian cancer susceptibility
genes.
J. A. Martignetti, P. Dottino, M. Babcock, L. Jara,
K. Moysich, L. Sucheston, S. Lele, K. Odunsi, S. Sanga.
3403
T
KiSS1
suppressor metastasis gene rs12998 and
rs5780218 polymorphisms in Mexican patients with
breast cancer.
M. C. Moran Moguel, S. E. Flores Martínez,
L. A. Juarez Aguilar, J. Sanchez Corona, I. P. Davalos
Rodriguez, R. C. Rosales Gomez, S. A. Gutierrez Rubio,
M. I. Torres Moran, E. G. Cruz Quevedo.
3404
F Initial viral load in cases of single human
papillomavirus 16 or 52 persistent infection is
associated with progression of later cytopathological
findings in the uterine cervix
K. Ohashi, K. Miura,
S. Abe, A. Kinoshita, S. Miura, D. Hamaguchi, K. Yoshiura,
H. Masuzaki.
3405
W Conventional and molecular cytogenetic
techniques in comparison with mRNA and DNA-based
quantitative real-time PCR to monitor minimal residual
disease in chronic myeloid leukemia.
I. S. Pagani,
C. Pirrone, D. Pigni, O. Spinelli, C. Boroni, T. Intermesoli,
U. Giussani, F. Pasquali, F. Lo Curto, A. Lanfranchi,
F. Porta, A. Rambaldi, G. Porta.
3406
T
ALK
gene copy number gain in a series of 350
NSCLC: A single institution experience.
L. Pecciarini,
A. Talarico, G. Grassini, E. Dal Cin, S. Foti, C. Lazzari,
V. Gregorc, M. G. Cangi, C. Doglioni.
3407
F Shortened telomere length and survival
in bladder cancer patients.
A. Russo, F. Modica,
S. Guarrera, G. Fiorito, A. Allione, B. Pardini, R. Critelli,
F. Ricceri, A. Bosio, G. Casetta, G. Cucchiarale,
P. Destefanis, P. Gontero, L. Rolle, A. Zitella, D. Fontana,
P. Vineis, C. Sacerdote, G. Matullo.
3408
W Generating hypotheses for targeted therapies
with cancer in silico drug discovery tools.
F. A. San
Lucas, J. Fowler, S. Kopetz, E. Vilar, P. Scheet.
3409
T Decreased gene expression and localization
of alkaline phosphatase (L/B/K) to the microvillus
membrane of renal cells in renal cell carcinoma.
U. Sharma, D. Pal, S. K. Singh, N. Kakkar, A. K. Mandal,
R. Prasad.
3410
F
Hif1a
and
PHD
gene expression levels in
CML patients.
A. Toylu, O. Altiok Clark, O. Salim,
A. Timuragaoglu, M. Okur, OK. Yucel, M. Ulubahsi, K. Eker
Guler, N. Sayin Ekinci, I. Karadogan, L. Undar.
3411
W Applicability of high-resolution multicapillary
electrophoresis for molecular characterization
of immune gene rearrangement profiles in acute
lymphoblastic leukemia.
H. Trautmann, M. Kozulic,
A.-W. Kruse, M. Kneba, M. Brüggemann.
3389
F Negotiating a minefield: Which variants to
return in a large prospective whole exome sequencing
project?
A. Church, E. Van Allen, E. Hiller, I. Rainville,
H. Rana, D. Treacy, K. Karalis, F. Huang, M. Giannakis,
F. Wilson, E. Stover, J. Bohkari, L. Sholl, N. Lindeman,
J. Garber, N. Wagle, L. Garraway.
3390
W Analysis of
BRAF
mutations (
BRAF
V600E
)
in
gliomas.
L. Da Silva, P. Vidigal, N. Binda, P. Couto,
L. Bastos-Rodrigues, L. De Marcp.
3391
T MtDNA copy number alteration and association
with clinicopathological features in breast cancer
patient.
M. Ghaffarpour, M. Houshmand.
3392
F TNFA-308 G
.
A is associated with HER-2/neu
expression in women with breast cancer.
L. Gomez-
Flores-Ramos, A. Escoto-De Dios, A. Ramos-Silva,
R. Ramirez-Patiño, I. Gutierrez-Hurtado, M. P. Gallegos-
Arreola.
3393
W The anti-cancer activity of propolis in colorectal
cancer.
M. Gunduz, G. Nas, M. Acar, O. F. Hatipoglu,
B. Yilmaz, G. Kaya, E. Gunduz.
3394
T Identification of complete hydatidiform
mole pregnancy-associated microRNAs in plasma.
Y. Hasegawa, K. Miura, A. Higashijima, S. Miura,
J. Tsukamoto, S. Abe, A. Kinoshita, H. Mishima,
K. Yoshiura, H. Masuzaki.
3395
F Eukaryotic translation initiation factor 4E (eIF4E)
expression is associated with breast cancer tumor
phenotype and predicts survival after anthracycline
chemotherapy treatment.
T. Heikkinen, T. Korpela,
R. Fagerholm, S. Khan, K. Aittomäki, P. Heikkilä,
C. Blomqvist, O. Carpén, H. Nevanlinna.
3396
W Personalized genomics of metformin therapy
for improved cancer survival.
C. C. Iverson, H. Xu,
Q. Chen, A. Shah, Q. Dai, J. Warner, N. B. Peterson,
L. Olson, D. C. Crawford, D. M. Roden, J. C. Denny,
M. C. Aldrich.
3397
T Comparison of mRNA expression profiles
in familial and sporadic breast cancers in Finnish
population.
S. Khan, P. Heikkilä, K. Aittomäki, C.
Blomqvist, H. Nevanlinna.
3398
F Discovering latent cancer characteristics
predictive of drug sensitivity.
D. A. Knowles, A. Battle,
D. Koller.
3399
W Prognostic significance of syndecan-1
expression in colorectal carcinoma.
S. H. Lee, E. J.
Choi, J. A. Yoon, E. S. Jung, S. Y. Kim.
3400
T Mutations and copy number changes identified
in primary brain tumors using complementary analyses
and formalin-fixed, paraffin-embedded tissue
A.
Ligon, B. Alexander, S. Ramkissoon, P. Wen, D. Reardon,
E. Lee, M. Rinne, A. Norden, L. Nayak, S. Nuland, L.
Doherty, D. Lafrankie, L. Brown, N. Arvold, S. Santagata,
I. Dunn, N. Lindeman, L. MacConaill, B. Rollins, R.
Beroukhim, K. Ligon.